Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Changli Wang

doi:10.1016/s2213-2600(18)30277-7

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue(Tianjin Medical University Cancer Institute and Hospital), Shidong Xu(Harbin Medical University), Qun Wang(Sun Yat-sen University), Xiaofei Li(Air Force Medical University), Yi Shen(Qingdao University), Heng Zhao(Shanghai Chest Hospital), Chun Chen(Union Hospital), Weimin Mao(Zhejiang Cancer Hospital), Wei Liu(First Bethune Hospital of Jilin University), Junfeng Liu(Hebei Medical University), Lanjun Zhang(Sun Yat-sen University Cancer Center), Haitao Ma(Soochow University), Qiang Li(Sichuan Cancer Hospital), Yue Yang(Peking University), Yongyu Liu(Liaoning Cancer Hospital & Institute), Haiquan Chen(Fudan University Shanghai Cancer Center), Changli Wang(Tianjin Medical University Cancer Institute and Hospital)

The Lancet Respiratory Medicine

August 24, 2018

10.1016/s2213-2600(18)30277-7

Cited by 293

Abstract

Related Papers

No related papers found

Powered by citation graph analysis